NCT Number: NCT03029117
Effect of Rheumatic Heart Disease on Maternal and Fetal Outcomes
It's prospective Cohort study to compare maternal and fetal outcomes in pregnant females between corrected and uncorrected rheumatic valve lesions
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
Female
Study type
Observational
About this study
Heart disease is one of the most important medical complications during pregnancy as it is one of the common, indirect obstetric causes of maternal death. Approximately 1% of pregnancies are complicated by cardiac disease .
Rheumatic heart disease (RHD) is the most common acquired heart disease in pregnancy RHD is a chronic acquired heart disorder resulting from acute rheumatic fever. In developing countries, RHD continues to be a major cause of cardiac morbidity and mortality especially among young adult females In pregnancies complicated with cardiac disorders, maternal and perinatal mortality and morbidity depend on the type of disorder, the functional status of the patient and the complications associated with the pregnancy.
Mitral stenosis is the most common valvular lesion in women with rheumatic heart disease, remains the most common acquired valvular lesion in pregnant women and the most common cause of maternal death from cardiac causes .
Although mortality is not high in women, the rate of fetal morbidity rises with the severity of mitral stenosis from 14% in pregnant patients with mild mitral stenosis , to 28% in women with moderate mitral stenosis and 33% in pregnant patients with severe mitral stenosis (area <1.5 CM2).
In the second and third trimesters, when maternal blood volume and cardiac output peak, heart failure may occur in pregnant women with moderate or severe mitral stenosis, even in previously asymptomatic women .
The rates of prematurity in fetus of women with rheumatic heart diseases are 20% to 30%, fetal growth restriction 5% to 20%, and stillbirth (1% to 3%).
The advancement in cardiology and obstetrics has provided major improvements in the management of pregnant patients with cardiac disorders. Now we are facing more women with previous history of surgical correction of rheumatic heart disease.
Vaginal delivery is considered In women with mild mitral stenosis, and in patients with moderate mitral stenosis ,. Even in women with severe MS in whom symptoms are New York Heart Association (NYHA) Class I-II without pulmonary hypertension, vaginal delivery is considered Cesarean section may be preferred in patients with severe mitral stenosis with NYHA Class III-IV symptoms, or who have pulmonary hypertension despite medical therapy.
Therapeutic options for in women with rheumatic heart disease include both medical and surgical alternatives, as well as catheter-based interventions The choice dependent on the degree of valvular affection and patient symptoms. There are few studies that compare the Maternal and fetal outcomes in women with rheumatic heart disease between patient with corrected and uncorrected valve lesions
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- pregnant females with rheumatic heart disease
Exclusion criteria
- other heart diseases ( cardiomyopathy , myocardial infarction ...etc.
Treatment and study plan
Primary outcomes
-
maternal morbidity
Time frame: 40 days after delivery
compare maternal morbidity between corrected and uncorrected valve lesions in pregnant women
Secondary outcomes
-
Fetal outcome
Time frame: first 1 day after delivery
compare birth weight and need for admission at neonatal intensive care unit (NICU) between corrected and uncorrected valve lesions in pregnant women
Sponsors and collaborators
Lead sponsor
Assiut University
Other
Registry information
Official study title
Prospective Cohort Study Compares Effect of Corrected and Uncorrected Rheumatic Heart Valve of Pregnant Women on Maternal and Fetal Outcomes
Important dates
- Study start
- 2016
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jan 24, 2017
- Registry last updated
- Jan 26, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CES1 Carriers in the PAPI Study
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsEvaluation of an AI-Based Lightweight ECG Telemetry Monitoring System
NCT07725445
Arrhythmias, Cardiac, Cardiac Arrhythmias
Seoul, South Korea
View Trial DetailsRemote ECG Monitoring-Based Phase I Cardiac Rehabilitation After Heart Surgery
NCT07736066
Cardiac Rehabilitation, Cardiac Surgery
Seoul, South Korea
View Trial DetailsThe Genetic Basis of Congenital Heart Disease in Africa
NCT01952171
Cardiovascular Abnormalities, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial Details